- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04502446
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)
March 20, 2024 updated by: CRISPR Therapeutics AG
A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell Malignancies
This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory T or B cell malignancies.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The study may enroll approximately 45 subjects in total.
Study Type
Interventional
Enrollment (Estimated)
45
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2050
- Research Site 3
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C1
- Research Site 7
-
-
-
-
California
-
Duarte, California, United States, 91010
- Research Site 2
-
Stanford, California, United States, 94305
- Research Site 5
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Research Site 10
-
-
Florida
-
Miami, Florida, United States, 33124
- Research Site 4
-
-
New York
-
Bronx, New York, United States, 10467
- Research Site 8
-
New York, New York, United States, 10065
- Research Site 9
-
-
Texas
-
Houston, Texas, United States, 77030
- Research Site 1
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Research Site 6
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria (abbreviated):
- Age ≥18 years.
- Confirmed diagnosis of a T cell malignancy or Diffuse Large B-Cell Lymphoma (DLBCL).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Adequate renal, liver, cardiac, and pulmonary organ function.
- Female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after CTX130 infusion.
Exclusion Criteria (abbreviated):
- Prior allogeneic stem cell transplant (SCT).
- Prior treatment with any anti-CD70 targeting agents.
- History of certain central nervous system (CNS), cardiac or pulmonary conditions.
- Active HIV, hepatitis B virus or hepatitis C virus infection.
- Previous or concurrent malignancy, except treated with curative approach not requiring systemic therapy and in remission for >12 months, or any other localized malignancy with low risk of developing into metastatic disease.
- Primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy.
- Prior solid organ transplantation.
- Pregnant or breastfeeding females.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CTX130
Administered by IV infusion following lymphodepleting chemotherapy.
|
CTX130 CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A (dose escalation)
Time Frame: From CTX130 infusion up to 28 days post-infusion
|
Incidence of adverse events
|
From CTX130 infusion up to 28 days post-infusion
|
Part B (cohort expansion)
Time Frame: From CTX130 infusion up to 60 months post-infusion]
|
Objective response rate
|
From CTX130 infusion up to 60 months post-infusion]
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression Free Survival
Time Frame: From date of CTX130 infusion until date of disease progression or death due to any cause, assessed up to 60 months
|
From date of CTX130 infusion until date of disease progression or death due to any cause, assessed up to 60 months
|
Overall Survival
Time Frame: From date of CTX130 until date of death due to any cause, assessed up to 60 months
|
From date of CTX130 until date of death due to any cause, assessed up to 60 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Alissa Keegan, PhD, CRISPR Therapeutics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 31, 2020
Primary Completion (Estimated)
March 1, 2027
Study Completion (Estimated)
May 1, 2027
Study Registration Dates
First Submitted
August 4, 2020
First Submitted That Met QC Criteria
August 4, 2020
First Posted (Actual)
August 6, 2020
Study Record Updates
Last Update Posted (Actual)
March 21, 2024
Last Update Submitted That Met QC Criteria
March 20, 2024
Last Verified
April 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRSP-ONC-004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on T Cell Lymphoma
-
University of Alabama at BirminghamTerminatedAnaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T-cell Lymphomas | Adult T-cell Leukemia | Adult T-cell Lymphoma | Peripheral T-cell Lymphoma Unspecified | T/Null Cell Systemic Type | Cutaneous t-Cell Lymphoma With Nodal/Visceral DiseaseUnited States
-
National Cancer Institute (NCI)WithdrawnHepatosplenic T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Adult T-cell Leukemia/Lymphoma | Extranodal NK-/T-cell Lymphoma, Nasal Type | Monomorphic Epiteliotrophic Intestinal T-cell LymphomaUnited States
-
BeiGeneCompletedCutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditionsChina, Taiwan, Germany, France, Canada, Italy
-
National Cancer Institute (NCI)CompletedPeripheral T-Cell Lymphoma (PTCL) | T-Cell Prolymphocytic Leukemia | Cutaneous T Cell Lymphoma (CTCL) | T-Cell Lymphoma Relapsed | Adult T-Cell Leukemia (ATL)United States
-
Samsung Medical CenterNational Cancer Center, Korea; Asan Medical Center; Yonsei University; Korea Cancer...CompletedCutaneous T Cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-negative | Angioimmunoblastic T Cell Lymphoma | Peripheral T Cell Lymphoma UnspecifiedKorea, Republic of
-
SciTech Development, LLCRush University Medical CenterRecruitingMycosis Fungoides | Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Cutaneous/Peripheral T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Classified | Primary Cutaneous T-cell Lymphoma | Cutaneous T-Cell Lymphoma, Unspecified | Follicular... and other conditionsUnited States
-
Deepa JagadeeshRecruitingAngioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Adult T-cell Leukemia/Lymphoma | Enteropathy Associated T-cell Lymphoma | Hepato-splenic T-cell Lymphoma | NK T-cell LymphomaUnited States
-
Shanghai General Hospital, Shanghai Jiao Tong University...SuspendedAngioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | Anaplastic Lymphoma | Acute T Cell Leukemia | T-lymphoblastic LymphomaChina
-
Legend Biotech USA IncActive, not recruitingT-Cell Lymphoma | Peripheral T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Recurrent | Peripheral T-Cell Lymphoma RecurrentUnited States
-
Washington University School of MedicineWugen, Inc.RecruitingAcute Myeloid Leukemia | Sezary Syndrome | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult T Cell Leukemia | Adult T Cell Lymphoma | Hepatosplenic T-cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | T-Cell Non-Hodgkin... and other conditionsUnited States
Clinical Trials on CTX130
-
CRISPR Therapeutics AGActive, not recruitingRenal Cell CarcinomaUnited States, Australia, Canada, Netherlands